MARKSANS PHARMA
Back to Balance Sheet
|
MARKSANS PHARMA Last 5 Year Total Non-Current Liabilities History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹94 Cr | ₹57 Cr | ₹24 Cr | ₹24 Cr | ₹17 Cr |
What is the latest Total Non-Current Liabilities ratio of MARKSANS PHARMA ?
Year | Total Non-Current Liabilities |
---|---|
Mar2023 | ₹94 Cr |
Mar2022 | ₹57 Cr |
Mar2021 | ₹24 Cr |
Mar2020 | ₹24 Cr |
Mar2019 | ₹17 Cr |
How is Total Non-Current Liabilities of MARKSANS PHARMA Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2023 | ₹94 Cr | 64.42 | |
Mar2022 | ₹57 Cr | 140.72 | |
Mar2021 | ₹24 Cr | -1.88 | |
Mar2020 | ₹24 Cr | 40.95 | |
Mar2019 | ₹17 Cr | - |
Compare Total Non-Current Liabilities of peers of MARKSANS PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
MARKSANS PHARMA | ₹7,665.9 Cr | 5.2% | -2.2% | 123.9% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹367,470.0 Cr | -0.9% | 0.9% | 62.6% | Stock Analytics | |
CIPLA | ₹112,990.0 Cr | 3.5% | 4.2% | 51.8% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹105,846.0 Cr | 12.2% | 18% | 103.8% | Stock Analytics | |
DIVIS LABORATORIES | ₹103,849.0 Cr | 0.8% | 5.6% | 19.3% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹96,742.1 Cr | -1% | -2.4% | 28.4% | Stock Analytics |
MARKSANS PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
MARKSANS PHARMA | 5.2% |
-2.2% |
123.9% |
SENSEX | 1.7% |
0.7% |
19.2% |
You may also like the below Video Courses